No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
WVE240621P5000
- 0.05
- 0.000.00%
15min DelayTrading Jun 18 12:53 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume135 Open Interest5.00Strike Price0.00Turnover890.11%IV-13.79%PremiumJun 21, 2024Expiry Date0.65Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.2294Delta0.8360Gamma87.00Leverage Ratio-2.5325Theta0.0000Rho-19.96Eff Leverage0.0001Vega
Intraday
- 5D
- Daily
Comments
$Wave Life Sciences(WVE.US$ got to love when good news tanks the price lol
$Wave Life Sciences(WVE.US$
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Wave Life Sciences announced positive results from their Phase 1b/2a SELECT-HD trial for WVE-003, a therapeutic for Huntington's disease (HD). The trial showed a statistically significant 46% reduction in mutant huntingtin (mHTT) protein in the cerebrospinal fluid compared to placeb...
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Wave Life Sciences announced positive results from their Phase 1b/2a SELECT-HD trial for WVE-003, a therapeutic for Huntington's disease (HD). The trial showed a statistically significant 46% reduction in mutant huntingtin (mHTT) protein in the cerebrospinal fluid compared to placeb...
1
$Wave Life Sciences(WVE.US$
NEWS
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
Wave Life Sciences announces continued momentum in GSK collaboration with the selection of two programs for development, initiation of clinical trials for the INHBE program in obesity, and upcoming presentations at key conferences. GSK collaboration progresses with an aggregate initiation payment of $12 million for two oligonucleotide programs using Wav...
NEWS
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
Wave Life Sciences announces continued momentum in GSK collaboration with the selection of two programs for development, initiation of clinical trials for the INHBE program in obesity, and upcoming presentations at key conferences. GSK collaboration progresses with an aggregate initiation payment of $12 million for two oligonucleotide programs using Wav...
Investors' optimism about strong revenue performance may have led to a high P/S ratio. However, with forecasted revenue decline, this high ratio may not be sustainable, posing a risk to shareholders and potential investors.
Read more